Piper Sandler Starts Acelyrin Inc (SLRN) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acelyrin (SLRN) risk/reward 'skewed to the upside'
May 30, 2023 1:26 PM EDTAcelyrin (NASDAQ: SLRN) was initiated at Overweight with a $29 price target by Morgan Stanley in a note Tuesday.
Analyst Vikram Purohit told investors that the company's late-stage immunology pipeline is addressing large areas of unmet needs.
"Acelyrin's lead pipeline program is izokibep," the analyst stated. "PhII data for... More
Morgan Stanley Starts Acelyrin Inc (SLRN) at Overweight
May 30, 2023 10:05 AM EDTMorgan Stanley analyst Vikram Purohit initiates coverage on Acelyrin Inc (NASDAQ: SLRN) with an Overweight rating and a price target of $29.00.
The analyst commented, "We initiate at Overweight with a $29 PT. PhII data for izokibep suggests strong potential for differentiation in I&I indications... More
